Asa Henin

Asa’s practice focuses on representing publicly traded life sciences companies as primary outside corporate and securities counsel. He advises management and boards of directors on US Securities and Exchange Commission (SEC) reporting and disclosure requirements, proxy statements and shareholder meetings, stock exchange requirements, corporate governance, investor communications, and other corporate and securities matters. Asa also advises companies in connection with their pre-initial public offering (IPO) crossover financings, IPOs, follow-on public offerings, and private investment in public equity (PIPE) financings. He is a member of Cooley’s public company advisory team (PCAT).

Asa’s representative transactions include:

• Allogene Therapeutics – $372.6 million IPO
• Kronos Bio – $287.5 million IPO 
• Longboard Pharmaceuticals – $84.8 million IPO
• Travere Therapeutics – $230.0 million follow-on equity offering
• Longboard Pharmaceuticals – $241.5 million follow-on equity offering
• Regulus Therapeutics – $100.0 million PIPE financing
• Tandem Diabetes Care – $316.0 million Rule 144A convertible note offering
• Allogene Therapeutics – $110.0 million underwritten nonpublic offering
• UroGen Pharma – $116.2 million follow-on equity offering